stockportfolio.pro
10x Genomics, Inc. (TXG)
Healthcare · Health Information Services · NasdaqGS
10x Genomics, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.08M | $146.31M | $245.89M | $298.85M | $490.49M | $516.41M | $618.73M | $610.78M | $642.82M |
| Gross profit | $60.52M | $117.65M | $184.86M | $240.38M | $416.40M | $396.02M | $409.31M | $414.48M | $443.88M |
| Net income | $-18.76M | $-112.48M | $-31.25M | $-542.73M | $-58.22M | $-166.00M | $-255.10M | $-182.63M | $-43.54M |
| Net margin | -26.4% | -76.9% | -12.7% | -181.6% | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
Source: 10x Genomics, Inc. SEC filings (10-K).
What growth is priced into TXG stock?
At today's market cap of $3.75B, 10x Genomics, Inc. is priced for free-cash-flow growth of about 12.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $130.12M from the FY ending 2025-12-31). For comparison, revenue 16.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 9 years of 10x Genomics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TXG in your portfolio →
10x Genomics, Inc. financial history by metric
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10x Genomics, Inc. — frequently asked questions
What is 10x Genomics, Inc.'s revenue?
10x Genomics, Inc. (TXG) reported revenue of $642.82M for fiscal year 2025, up 5.2% from the prior year, according to its SEC filings.
Is 10x Genomics, Inc. profitable?
No — TXG reported a net loss of $-43.54M in fiscal 2025.
What is TXG's P/E ratio?
10x Genomics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is 10x Genomics, Inc. growing?
TXG's revenue grew at roughly 16.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does 10x Genomics, Inc. have?
As of fiscal year 2025, TXG carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is 10x Genomics, Inc.'s gross margin?
TXG's gross margin was 69.1% in fiscal 2025 — gross profit of $443.88M on revenue of $642.82M.
What is 10x Genomics, Inc.'s market cap?
10x Genomics, Inc. (TXG) has a market capitalization of about $3.75B, based on the latest data in our nightly-refreshed cache.
When does 10x Genomics, Inc.'s fiscal year end?
TXG's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into TXG stock?
At today's market cap of $3.75B, 10x Genomics, Inc. is priced for free-cash-flow growth of about 12.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $130.12M from the FY ending 2025-12-31). For comparison, revenue 16.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from 10x Genomics, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.